Risk factors for severe complications of colonoscopy in screening programs.


Journal

Preventive medicine
ISSN: 1096-0260
Titre abrégé: Prev Med
Pays: United States
ID NLM: 0322116

Informations de publication

Date de publication:
01 2019
Historique:
received: 01 06 2018
revised: 05 10 2018
accepted: 07 11 2018
pubmed: 12 11 2018
medline: 18 2 2020
entrez: 12 11 2018
Statut: ppublish

Résumé

Severe complications (SC) in colonoscopy represent the most important adverse effect of colorectal cancer screening programs (CRCSP). The objective is to evaluate the risk factors for SC in colonoscopy indicated after a positive fecal occult blood test in population-based CRCSP. The SC (n = 161) identified from 48,730 diagnostic colonoscopies performed in a cohort of all the women and men invited from 2000 to 2012 in 6 CRCSP in Spain. A total of 318 controls were selected, matched for age, sex and period when the colonoscopy was performed. Conditional logistic regression models were estimated. The analysis was performed separately in groups: immediate-SC (same day of the colonoscopy); late-SC (between 1 and 30 days after); perforation; and bleeding events. SC occurred in 3.30‰ of colonoscopies. Prior colon disease showed a higher risk of SC (OR = 4.87). Regular antiplatelet treatment conferred a higher risk of overall SC (OR = 2.80) and late-SC (OR = 9.26), as did regular anticoagulant therapy (OR = 3.47, OR = 7.36). A history of pelvic-surgery or abdominal-radiotherapy was a risk factor for overall SC (OR = 5.03), immediate-SC (OR = 8.49), late-SC (OR = 4.65) and perforation (OR = 21.59). A finding of adenoma or cancer also showed a higher risk of overall SC (OR = 8.71), immediate-SC (OR = 12.67), late-SC (OR = 4.08), perforation (OR = 4.69) and bleeding (OR = 17.02). The risk of SC doesn't vary depending on the type of preparation or type of anesthesia. Knowing the clinical history of patients such as regular previous medication and history of surgery or radiotherapy, as well as the severity of the findings during the colonoscopy process could help to focus prevention measures in order to minimize SC in CRCSP.

Identifiants

pubmed: 30414944
pii: S0091-7435(18)30355-4
doi: 10.1016/j.ypmed.2018.11.010
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

304-308

Informations de copyright

Copyright © 2018 Elsevier Inc. All rights reserved.

Auteurs

Mercedes Vanaclocha-Espi (M)

Cancer and Public Health Area, FISABIO - Public Health, Valencia, Spain.

Josefa Ibáñez (J)

Cancer and Public Health Area, FISABIO - Public Health, Valencia, Spain; General Directorate Public Health, Valencian Community, Spain.

Ana Molina-Barceló (A)

Cancer and Public Health Area, FISABIO - Public Health, Valencia, Spain.

María José Valverde-Roig (MJ)

General Directorate Public Health, Valencian Community, Spain.

Elena Pérez (E)

General Directorate Public Health, Valencian Community, Spain.

Andreu Nolasco (A)

University of Alicante, Spain.

Mariola de la Vega (M)

General Directorate of Assistance Programs, Canarias, Spain.

Isabel Diez de la Lastra-Bosch (ID)

General Directorate of Assistance Programs, Canarias, Spain.

María Elena Oceja (ME)

General Directorate Public Health, Cantabria, Spain.

Josep Alfons Espinàs (JA)

Catalan Cancer Strategy, Department of Health, Catalonia, Spain; Biomedical Research Institute, Bellvitge, (IDIBELL) - L'Hospitalet de LLob, Barcelona, Spain.

Rebeca Font (R)

Catalan Cancer Strategy, Department of Health, Catalonia, Spain; Biomedical Research Institute, Bellvitge, (IDIBELL) - L'Hospitalet de LLob, Barcelona, Spain.

Francisco Pérez-Riquelme (F)

General Directorate Public Health, Murcia, Spain; Biomedical Research Institute of Murcia (IMIB-Arrixaca-UMU), University Clinical Hospital Virgen de la Arrixaca, University of Murcia, Spain.

Eunate Arana-Arri (E)

Biocruces Research Institute, Barakaldo, Spain.

Isabel Portillo (I)

The Basque Health Service, Basque Country, Spain.

Dolores Salas (D)

Cancer and Public Health Area, FISABIO - Public Health, Valencia, Spain; General Directorate Public Health, Valencian Community, Spain. Electronic address: salas_dol@gva.es.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH